Results 201 to 210 of about 80,403 (271)

Therapeutic Management in an <i>AGRN</i>-Related Congenital Myasthenic Syndrome Patient. [PDF]

J Clin Neurol
Erturk AY, Kurt I, Mammadov O, Sengun IS.   +3 more
europepmc   +1 more source

Prurigo nodularis: case series of 28 Brazilian patients treated with psychotropic medications. [PDF]

An Bras Dermatol
Gerlero P, Ilvay-Mendoza SS, Dwan AJ, Nico MMS.   +3 more
europepmc   +1 more source

Bridging Literature and Real-World Evidence: External Evaluation and Development of Fluoxetine Population Pharmacokinetics Model. [PDF]

Pharmaceutics
Han B, Xu N, Ma C, Ju G, Xi X, Qian C, Guo N, Liu X, Zhu X, Li C, Liu L.   +10 more
europepmc   +1 more source

Antidepressant Augmentation of Antipsychotic Treatment in Schizophrenia: A Narrative Review. [PDF]

Med Sci Monit
Li W, Gao B, Liu Y, He W, Zha W, Du S, Zeng Y, Zhang Y.   +7 more
europepmc   +1 more source

Leveraging developmental neurotoxicity data in zebrafish embryos through the use of artificial intelligence methods. [PDF]

Front Toxicol
Heusinkveld HJ, Hessel EVS, Zwart EP, Gremmer ER, Pennings JLA.   +4 more
europepmc   +1 more source

Serotonin Syndrome Versus Neuroleptic Malignant Syndrome in a Pediatric Patient Receiving Fluoxetine and Haloperidol: A Case Report. [PDF]

J Pediatr Pharmacol Ther
Aráez PMB, Turner S.
europepmc   +1 more source

Enhanced CYP2C19-mediated drug-drug interaction risk with escitalopram in geriatric populations. [PDF]

Front Pharmacol
Byoun S, Heo DG, Lee M, Lee R, Li Y, Lee JY, Hong E, Lee W.   +7 more
europepmc   +1 more source

Cytoplasmic TDP-43 leads to early behavioral impairments without neurodegeneration in a serotonergic neuron-specific C. elegans model. [PDF]

Sci Rep
Lacour A, Vassallu F, Romussi S, Rayes D, Igaz LM.   +4 more
europepmc   +1 more source